T. Rowe Price Associates
PCVX icon

T. Rowe Price Associates’s Vaxcyte PCVX Stock Holding History

T. Rowe Price Associates’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$174M Buy
2,988,999
+2,012,570
+206% +$109M 0.02% 542
2026
Q1 		$56.7M Sell
976,429
-198,910
-17% -$10.8M 0.01% 737
2025
Q4 		$54.2M Sell
1,175,339
-513,144
-30% -$23M 0.01% 794
2025
Q3 		$60.8M Sell
1,688,483
-1,481,764
-47% -$49.1M 0.01% 744
2025
Q2 		$103M Sell
3,170,247
-371,760
-10% -$12.2M 0.01% 564
2025
Q1 		$134M Sell
3,542,007
-424,949
-11% -$34M 0.02% 508
2024
Q4 		$325M Sell
3,966,956
-499,181
-11% -$49.6M 0.04% 335
2024
Q3 		$510M Buy
4,466,137
+1,292,970
+41% +$117M 0.06% 273
2024
Q2 		$240M Sell
3,173,167
-3,014
-0.1% -$205K 0.03% 390
2024
Q1 		$217M Buy
3,176,181
+498,359
+19% +$34.5M 0.03% 410
2023
Q4 		$168M Buy
2,677,822
+260,170
+11% +$13.5M 0.02% 440
2023
Q3 		$123M Buy
2,417,652
+225,270
+10% +$11.1M 0.02% 476
2023
Q2 		$109M Buy
2,192,382
+2,160,354
+6,745% +$102M 0.02% 507
2023
Q1 		$1.2M Buy
32,028
+1,760
+6% +$74.7K ﹤0.01% 1687
2022
Q4 		$1.45M Buy
30,268
+21,717
+254% +$852K ﹤0.01% 1592
2022
Q3 		$206K Sell
8,551
-5,377
-39% -$136K ﹤0.01% 2534
2022
Q2 		$303K Buy
13,928
+1,220
+10% +$28.2K ﹤0.01% 2436
2022
Q1 		$307K Buy
12,708
+1,127
+10% +$24.6K ﹤0.01% 2540
2021
Q4 		$276K Sell
11,581
-800
-6% -$18.6K ﹤0.01% 2627
2021
Q3 		$314K Buy
12,381
+2,042
+20% +$49.5K ﹤0.01% 2561
2021
Q2 		$233K Buy
+10,339
New +$212K ﹤0.01% 2669

Other funds holding PCVX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

T. Rowe Price Associates's PCVX Position: Q2 2026 in Review

T. Rowe Price Associates increased its Vaxcyte (PCVX) stake by 206% in Q2 2026, buying an estimated $109M and bringing the position to 2,988,999 shares worth $174M. The position accounts for 0.02% of the portfolio, ranked #542.

T. Rowe Price Associates first reported a position in PCVX in Q2 2021 and has held it in 21 quarters since. The position peaked at $510M in Q3 2024. 331 funds tracked by Wall St. Rank hold PCVX as of Q2 2026.

  • T. Rowe Price Associates held 2,988,999 shares of Vaxcyte worth $174M as of Q2 2026.
  • T. Rowe Price Associates bought 2,012,570 Vaxcyte shares in Q2 2026, an estimated $109M.
  • Vaxcyte made up 0.02% of T. Rowe Price Associates's portfolio in Q2 2026, its #542 holding.
  • T. Rowe Price Associates first reported a position in Vaxcyte in Q2 2021 and has held it in 21 quarters since.
  • T. Rowe Price Associates's Vaxcyte position peaked at $510M in Q3 2024.
  • 331 funds tracked by Wall St. Rank held Vaxcyte as of Q2 2026.

Based on T. Rowe Price Associates's 13F filing for Q2 2026, filed 14 Aug 2026.